Athenex Inc. and its partner Almirall SA have achieved the primary endpoint of 100% clearance of actinic keratosis lesions at Day 57 in two Phase III trials of the topical ointment KX2-391. Data details are yet to be unveiled, but based on earlier trial results the drug is thought to be less efficacious than some marketed therapies. Nevertheless, its ease of administration and favorable local skin reaction profile position it well to take market share.
Informa's Biomedtracker raised its likelihood of approval estimate by eight percentage points to 70% after the positive trial results were...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)